gl-onc1
Biologicalexperimental
Clinical trial activity
9 trials · 9 clinical orgs · 0 marketing orgs
Phase 1
6
Phase 2
3
Phase 3
1
Phase 4
0
Earliest trial started Nov 1, 2008 (NCT00794131)
Timeline
Indications
Mechanism of action
- Oncolytic virusOTHER
Oncolytic virus other
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4594308 ↗
Also known as
- gl-onc1
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06463665 | Phase 2 | Sep 26, 2024 | Genelux, Newsoara Biopharma Co., Ltd. |
| NCT05281471 | Phase 3 | Aug 31, 2022 | Genelux, GOG Foundation, Inc. |
| NCT02759588 | Phase 1 | May 1, 2016 | Advent Health, Genelux |
| NCT02714374 | Phase 1 | Mar 1, 2016 | Genelux, University of California, San Diego |
| NCT01766739 | Phase 1 | Jan 1, 2013 | Cornell University, Genelux |
| NCT01584284 | Phase 1 | Apr 1, 2012 | Genelux, University of California, San Diego |
| NCT01443260 | Phase 1/Phase 2 (Phase 2) | Feb 1, 2012 | Genelux, University of Tuebingen |
| NCT00794131 | Phase 1 | Nov 1, 2008 | Genelux, Royal Marsden Hospital NHS Trust, University of London |
| NCT03420430 | N/A | — | Genelux |
Showing 9 of 9 trials
Page 1 / 1
Organizations
Research & Development (9)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Genelux | For profit | 9 | 7 | 4 | 2008 |
| University of California, San Diego | Academic/Hospital | 2 | 1 | 1 | 2012 |
| Advent Health | Academic/Hospital | 1 | 0 | 1 | 2016 |
| Cornell University | Academic/Hospital | 1 | 1 | 1 | 2013 |
| GOG Foundation, Inc. | Academic/Hospital | 1 | 0 | 1 | 2022 |
| Newsoara Biopharma Co., Ltd. | For profit | 1 | 0 | 1 | 2024 |
| Royal Marsden Hospital NHS Trust | Academic/Hospital | 1 | 0 | 1 | 2008 |
| University of London | Academic/Hospital | 1 | 0 | 1 | 2008 |
| University of Tuebingen | Academic/Hospital | 1 | 0 | 1 | 2012 |
9 organizations
Page 1 / 1